-
-
-
-
-
-
-
Clear Street Launches Healthcare & Biotechnology Equity Research
-
-
-
-
-
-
-
Mizuho Securities Upgrades Immuneering Corporation (IMRX) to Buy
-
-
-
-
-
-
-
Merck (MRK) Pops After Beat-and-raise, Analyst Praises a 'Strong' Beat
-
-
-
-
-
-
-
Mizuho Securities Reiterates Buy Rating, $95 Price Target on Incyte (INCY)
-
-
-
-
-
-
-
Mizuho Securities Reiterates Buy Rating, $20 PT on eFFECTOR Therapeutics (EFTR) Following CMO Departure, Sees Upcoming Phase IIa zotatifin Data as Key to Pipeline Validation
-
-
-
-
-
-
-
Mizuho Securities Reiterates Buy Rating on Xencor (XNCR), Sees Multiple Opportunities
-
-
-
-
-
-
-
Mizuho Americas Hires Graig C. Suvannavejh, PhD, as Senior Biopharmaceuticals and Biotechnology Analyst
-
190 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

